Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE
Title Image

LSK BioPharma at ASCO 2015


LSKB announces initiation of a US clinical trial studying the dose escalation and safety of apatinib mesylate (YN968D1) in solid tumor cancers


LSK BioPharma and Huntsman Cancer Institute Announce an Exclusive License Agreement for HCI-1401, a BTK inhibitor for treatment of B-cell malignancies and other diseases